Phase 2a clinical trial of IRL-201805 for autoimmune indication
Latest Information Update: 25 May 2023
At a glance
- Drugs IRL 201805 (Primary)
- Indications Autoimmune disorders
- Focus Therapeutic Use
Most Recent Events
- 25 May 2023 New trial record
- 22 May 2023 According to a Revolo Biotherapeutics media release, the company is nearing initiation of this trial.